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Abstract
 Purpose—Differential diagnostic evaluation associated with a drug may bias effect estimates 
due to an increased detection of preclinical outcomes. Persistent cough is a common side effect 
with angiotensin-converting enzyme inhibitors (ACEI) and we hypothesized that ACEI initiators 
would undergo more diagnostic evaluations, potentially leading to diagnosis of preclinical lung 
cancer. We compared the incidence of cough-related diagnostic evaluations and lung cancer 
among ACEI versus angiotensin receptor blockers (ARB) initiators.
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 Methods—Using a 20% sample of Medicare claims 2007–2012, we identified initiators of 
ACEI or ARB, age 66–99 years. Incidence of diagnostic evaluation and lung cancer were 
compared using adjusted Cox models. Monthly probabilities of workup were compared using 
proportion differences.
 Results—There were 342,611 and 108,116 ACEI and ARB initiators, respectively. Monthly 
probability of chest X-rays ranged from minimum 4.7% to maximum 21.2% in the 6 months pre 
and post-initiation. Differences in incidence of diagnostic procedures in the 6 months after 
initiation were only minimal (chest X-rays hazard ratio (HR) = 1.12; 95% CI: 1.10–1.14), chest-
MRI (0.86, 95% CI: 0.74–0.99), CT-scans (1.09, 95% CI: 0.99–1.18) or bronchoscopies (1.03, 
95% CI: 0.83–1.29)). Proportion differences for chest X-rays peaked in the month pre-initiation 
(8.4%, 95% CI: 8.1–8.6) but negligible thereafter. There was no difference in the incidence of lung 
cancer among ACEI versus ARB initiators (HR=0.99, 95% CI: 0.84–1.16).
 Conclusion—Results indicate minimal differential chest workup after ACEI vs ARB initiation 
and no difference in lung cancer incidence, but suggest differential workup in the month before the 
first recorded prescription. The latter may reflect drug use before the first observed pharmacy 
claim or increased workup before initiation of ACEI therapy.
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 Introduction
In cohort studies, detection bias occurs when the exposure influences or triggers the search 
for the outcome.1 For example, if a drug is known to be associated with side effects, patients 
on the drug may be subjected to increased diagnostic evaluation to monitor those specific 
side effects relative to non-users or users of a comparator drug. Differential diagnostic 
evaluation may lead to increased or earlier discovery of a possibly more serious outcome in 
those using the drug, therefore introducing a spuriously higher incidence of the outcome 
above and beyond any potential causal effect of the drug on the outcome.
We sought to investigate differential diagnostic evaluation in a study comparing the initiation 
of two antihypertensives - angiotensin converting enzyme inhibitor (ACEI) and angiotensin 
II receptor blockers (ARB) which are both recommended initial treatment of hypertension 
according to the Joint National Committee 7 (JNC7) guidelines.2 Persistent dry cough is a 
common side effect associated with ACEI drugs, reported in 5–35% of the patients treated 
with ACEI.3,4 The onset of cough may range from a few hours after the initial dose to weeks 
or months after starting therapy and is not dose-dependent.4–6 If discontinuation of ACEI is 
required because of cough, an ARB is commonly substituted. The incidence of cough with 
ARB is similar compared to placebo and less than ACEI in patients intolerant to previous 
ACEI therapy.7–9
Given an increased incidence of cough with ACEI, patients starting ACEI may undergo 
more diagnostic evaluation for cough (chest X-rays, chest CT-scan, chest-MRI, 
bronchoscopy) compared to patients starting ARB. An increase in diagnostic evaluations for 
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cough may lead to earlier/increased detection of preclinical lung cancer and therefore a 
spuriously higher incidence of lung cancer with ACEI versus ARB early after initiation. 
There is mixed evidence about lung cancer risk with ACEI versus ARB based on two 
epidemiologic studies, with one study finding a null association and another a slightly 
increased risk.10,11 An observed increased incidence of diagnostic evaluation followed by a 
higher short term incidence of lung cancer in ACEI versus ARB initiators could be 
suggestive of detection bias. While plausible, to our knowledge, limited data exist 
quantifying differential diagnostic evaluations and thus we compared common cough-related 
diagnostic procedures between ACEI and ARB initiators in order to assess the potential for 
differential diagnostic evaluation. We first investigated the monthly probability of diagnostic 
evaluation and hypothesized that the probability with ACEI and ARB would be similar 
before drug initiation, would be higher among ACEI initiators shortly after drug initiation, 
and taper off thereafter. Next we compared the overall incidence of diagnostic evaluation 
with ACEI and ARB in the 6 months after drug initiation and hypothesized that the 
incidence would be higher in ACEI versus ARB initiators. Finally we compared the 
incidence of lung cancer among initiators of ACEI versus ARB.
 Methods
We conducted a new-user active-comparator cohort study12 using a 20% random sample of 
Medicare claims from 2007–2012. This sample includes beneficiaries with fee-for-service 
Part A, B and D enrollment in at least one month from January 1, 2007 to December 31, 
2012. Medicare is the largest public health insurance program in the US and contains 
information about demographics and enrollment, diagnoses, procedures and prescription 
drugs.13,14
From this data source, we identified new-users of ACEI and ARB, 66–99 years of age, who 
had no dispensed prescriptions of either ACEI or ARB in the preceding 12 months. Initiation 
was defined as the first prescription of the above drugs, with the date of initiation as the 
index date. Eligible patients were required to be continuously enrolled for at least 12 months 
in Parts A, B and D before the index date. Since prevalent cancers may affect the incidence 
of diagnostic evaluation or lung cancer, we excluded patients with any evidence of prevalent 
cancer, cancer treatment or cancer related follow-up examinations identified using 
International Classification of Diseases Ninth Revision (ICD-9-CM), Current Procedural 
Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes 
(supplemental table 1).
The outcomes for aim 1 were diagnostic evaluation procedures commonly used for 
persistent cough (chest X-rays, chest MRIs, chest CT-scans and bronchoscopies) defined 
using CPT or ICD-9-CM procedure codes (supplemental table 2) from inpatient and 
outpatient claims. We compared the monthly probability (number of patients with at least 
one procedure in that month/total patients in the cohort) of cough-related diagnostic 
procedures for ACEI versus ARB initiators using age, sex and race-adjusted proportion 
(probability) differences and 95% confidence intervals in the 6 months pre and post 
initiation, estimated using additive binomial regression models. For this analysis, we 
required patients to be continuously enrolled for at least 6 months after the index date. We 
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also fit an adjusted Cox model to compare the incidence of diagnostic evaluation in the 6 
months after initiation without requiring continuous enrollment after the index date. Patients 
were followed from their index prescription to the earliest of the following events: 
occurrence of a cough-related diagnostic procedure, switching/discontinuation or 
augmentation of therapy, death, end of enrollment, December 31, 2012, or 6 months after 
index date.
Next we compared the incidence of lung cancer among ACEI and ARB initiators using 
adjusted Cox models. For this analysis, we further restricted the study cohort to initiators 
who filled a second script of the same drug class within 180 days of the index date. Follow-
up started at the second prescription date and ended at the earliest of lung cancer, switching/
discontinuation/augmentation, death, end of enrollment or December 31, 2012. Lung cancer 
was defined as at least two inpatient or outpatient claims with ICD-9-CM codes 162.xx 
within two months, a definition with high specificity (minimizes false positives, yields 
unbiased relative risk estimates) in a Medicare population.15
We adjusted for confounders using propensity scores (PS) estimated using demographic 
characteristics, baseline diagnostic evaluation and healthcare utilization, comorbidities and 
use of other medications including other antihypertensives measured before the index 
date.16–18 We implemented the PS using weights that led to “standardization” of covariates 
in the ARB group to the covariate distribution observed in the ACEI group. Specifically, we 
assigned a weight of 1 for ACEI and a weight of (PS/(1-PS)) for ARB.19,20 This weighting 
creates a pseudo-population of ARB initiators with measured patient characteristics similar 
to those observed in ACEI initiators. This balance of patient characteristics allows us to 
estimate the unconfounded treatment effect in a population of patients similar to those 
actually initiating ACEI under the assumption of no unmeasured confounding.19,21 We 
computed weighted Kaplan-Meier plots to check the proportional hazards assumption and 
then fit weighted Cox proportional hazards models with treatment as the only independent 
variable to compare incidence of diagnostic evaluation and lung cancer among initiators of 
ACEI and ARB. We also examined the frequency and incidence of chest X-rays in the six 
months following the index date stratifying by the presence of baseline chronic obstructive 
pulmonary disease (COPD) or congestive heart failure (CHF) – conditions for which X-rays 
are commonly indicated.
 Results
Table 1 presents the baseline covariate distribution for the new-user cohorts. Compared with 
the ARB initiators, ACEI initiators were more likely to be male and white. Mean age was 
around 76 years in both groups. ACEI initiators were less likely to have connective tissue 
disease, diabetes complications, or have ECG, blood tests, influenza vaccinations, and lipid 
panels performed compared with the ARB initiators. After weighting, the distribution of all 
covariates in the weighted ARB pseudo-population was virtually identical to the distribution 
observed in ACEI initiators (standardized mean differences <5%). This balance of measured 
covariates effectively eliminates confounding by those variables, although some level of 
residual or unmeasured confounding may still exist.
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There were 342,611 and 108,611 eligible initiators of ACEI and ARB, respectively, during 
the study period. Of these, 295,604 ACEI initiators and 93,284 ARB initiators were 
continuously enrolled for at least 6 months post-index. The monthly probability of having a 
chest X-ray ranged (minimum to maximum) from 4.8% to 21.2% in ACEI and 4.8% to 
12.2% in the ARB group (supplemental table 3). The proportion difference comparing ACEI 
and ARB groups was the highest in the month before the index date (Proportion difference 
8.37, 95% CI: 8.12–8.63) and decreased in the following months (figure 1). We also 
examined the distribution of days when chest X-rays were conducted in the month before 
initiation and found the median to be 8 days before initiation among ACEI initiators and 10 
days before initiation among ARB initiators. The monthly proportion differences for other 
diagnostic procedures were more or less constant in the 6 months before and after the index 
date (supplemental table 3).
Table 2 presents the event rates per 100,000 person-months, median time-to-event, and the 
crude and adjusted (weighted) hazard ratios for the incidence of diagnostic evaluation in the 
6 months after the index date. A total of 90,951 (26.5%) ACEI initiators and 24,123 (22.3%) 
ARB initiators had at least one chest X-ray in the 6 months after drug initiation. The 
weighted HR comparing incidence of chest X-rays among ACEI and ARB initiators was 
1.12 (95% CI: 1.10–1.14). The corresponding HRs for chest MRI (0.86, 95% CI: 0.74–
0.99), chest CT-scans (1.09, 95% CI: 0.99–1.18), and bronchoscopies (1.03, 95% CI: 0.83–
1.29) were all close to 1 suggesting minimal increased hazard of diagnostic evaluation with 
ACEI vs ARBs in the 6 months after drug initiation. Based on 902 lung cancers among 
238,439 ACEI initiators and 261 lung cancers among 72,626 ARB initiators over 0.7 median 
years of follow-up, no increased risk of lung cancer was found with ACEI versus ARB 
(HR=0.99; 95% CI: 0.84–1.16; table 3).
 Discussion
We hypothesized that the incidence of diagnostic evaluation for cough would be 
substantially higher in the months immediately following drug initiation among ACEI versus 
ARB initiators which could lead to detection bias in any study of cancers, specifically of 
lung cancer. Contrary to our hypothesis, we found only minimal differences in the diagnostic 
procedures in the 6 months after initiation of ACEI versus ARB based on time-to-event 
analyses. While small differences existed (12–14%), these may not be enough to account for 
a spuriously increased incidence of lung cancer with ACEI versus ARB that we wanted to 
explore.
Given the minimal differences in the incidence of diagnostic evaluations in ACEI and ARB 
patients after drug initiation, we expected no difference in the incidence of lung cancer with 
ACEI versus ARB, and that is what we observed. Thus, lung cancer incidence might be 
considered in this setting as a negative control outcome.22,23 Smoking is an important 
confounder of the relationship between ACEI vs ARB and lung cancer; but it is unmeasured 
in Medicare claims. However we adjusted for baseline claims for tobacco use and this and 
all other covariates were balanced both before and after weighting. The observation of a null 
association suggests minimal differences in smoking between ACEI and ARB initiators (and 
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therefore no major concern for confounding by smoking) in this study, but this is beyond the 
scope of this paper.
Examination of monthly proportion differences comparing ACEI and ARB initiators showed 
some indication of differential chest X-rays in the days around the index date. Contrary to 
our expectation, however, the proportion difference was the highest in the month before 
initiation (as defined by the first record of a dispensed prescription) instead of post-
initiation. Several possibilities could explain the peak in the proportion difference in the 
month before initiation. First, because ACEI are known to be associated with persistent 
cough, it is possible that more ACEI initiators were subject to X-rays to check the lungs 
before starting therapy. A second and possibly more plausible reason is that we are missing 
the true ‘initiation’ of drug therapy, i.e., it is possible that initiators defined by our algorithm 
may have been on drug therapy a few days or weeks before their first dispensed prescription 
was captured in claims.
While speculative, the observed difference prior to the first recorded drug dispensing could 
be explained if patients were given free drug samples by their physicians as observed in 
some other settings.24,25 However, both ACEI and ARB are widely available as inexpensive 
generics.26 In our cohort, >99% of ACEI and about 50% of the ARB prescriptions were for 
generic versions compatible with less sample use for ACEI. Missing the initial period of 
drug use could also be partly attributable to patients filling some prescriptions outside of the 
context of part D for example through dual eligibility with pharmacy benefit programs like 
the Veterans Affairs coverage or out-of-pocket payment particularly after the introduction of 
low-cost generic programs, although we do not have the relevant data to evaluate this 
possibility.27 This points to a potential limitation of the new-user design based on pharmacy 
claims which has implications for studying short term outcomes, drug safety and definition 
of baseline covariates potentially affected by treatment.24
One strength of our study is the use of an active comparator which is a therapeutic 
alternative to ACEI therapy. Use of an active comparator with the same indication as that of 
ACEI synchronized patients with respect to disease severity and baseline characteristics and 
limited confounding by these factors.28,29 Table 1 reflects the covariate balance achieved by 
our study design (crude) and remaining differences of measured covariates were greatly 
reduced by propensity score weighting. Given that many covariates were already balanced 
by using an active comparator new user design (even before propensity score 
implementation), unmeasured confounding might not be a major concern in our study, 
although it cannot be ruled out.
Compared to other procedures, the proportion of ACEI and ARB initiators with at least one 
chest X-ray in the 6 months post initiation was much higher (about 22–26%). On closer 
examination, we found that 98% of the chest X-rays were coded using CPT codes 71010 
(Radiologic examination, chest; single view, frontal) and 71020 (Radiologic examination, 
chest, two views, frontal and lateral). A study by Levin et al examining the trends in 
utilization of cardiothoracic imaging procedures in Medicare fee-for-service beneficiaries 
found about 94 chest X-rays per 100 beneficiaries in 2005.30 We found a similar high rate of 
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chest X-ray use (92 per 100 beneficiaries) in our entire 20% Medicare claims sample 
indicating that our data represent chest X-ray utilization well (data not presented).
We also examined the frequency of chest X-rays in our new-user cohort stratified by CHF 
and COPD, conditions for which chest X-rays are likely to be indicated. As expected, about 
36–42% of the ACEI or ARB initiators with CHF or COPD at baseline had at least one 
incident chest X-ray in the 6 months after initiation while only a quarter of those without 
either of the two conditions had at least one claim for chest X-rays (supplemental table 4). 
The difference in monthly probability of chest X-rays peaked in the month just before drug 
initiation in all subgroups (data not shown). Finally, to provide contrast to the observation of 
a peak in chest X-rays in the month before initiation, we examined the monthly proportion 
differences of a ‘control’ diagnostic evaluation (hip X-rays) and found no substantial peak in 
the 6 months before and after initiation (supplemental table 5).
Our study had some limitations. Our analyses of differences in monthly proportions of 
diagnostic testing were adjusted only for age, sex and race, and should therefore be 
interpreted with caution. We did not conduct analyses with time-varying covariates since 
some of the covariates (example, baseline diagnostic procedures) might be affected by 
treatment in this setting. Second, it is possible that some ‘new-users’ of ARB used ACEI 
prior to the 12 month washout period and discontinued ACEI because of cough. For such 
patients, the diagnostic evaluation before the initiation of ARB may seem elevated (due to 
the prior ACEI therapy). It seems unlikely, however, that the differences would be minimal 
throughout the six-month pre-index period and then peak at one month before initiation 
under this hypothesis. It is also possible that patients undergoing diagnostic work-up for 
persistent cough after receiving an ACEI sample would be less likely to fill a prescription for 
ACEI and are therefore missing from our study. The proportion of such patients is expected 
to be low, however, given the availability of several low-cost generic versions of ACEI drugs 
and the resultant low potential for sample use. Third, there are no validated algorithms to 
identify cough-related diagnostic evaluations, to our knowledge. However we used a 
comprehensive list of codes based on substantive knowledge and expert opinion. Fourth, our 
cohort of initiators of antihypertensive monotherapy should mainly consist of stage 1 
hypertension patients (but this is empirically unverifiable due to absence of blood pressure or 
stage data). Further, patients were allowed to be on other antihypertensive drugs during the 
washout period and this information was used in the estimation of propensity scores. A 
sensitivity analysis excluding patients with use of any antihypertensive drug during washout 
period resulted in very similar estimates (supplemental table 6). To explore the potential for 
effect modification by hypertension stage, we compared same-day initiators of ACEI plus 
thiazide versus ARB plus thiazide (proxy for stage 2 hypertension) and found no difference 
in the incidence of chest X-rays in the 6 months post-index (supplemental table 7). Finally, 
our analyses were based on initiators of antihypertensives in the Medicare population and 
generalizability is therefore restricted to older adults on the Medicare fee-for-service plan or 
in health care settings with similar drug use or prescribing behaviors.
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We found minimal differences in diagnostic evaluation in the 6 months after initiation and 
no difference in the incidence of lung cancer with ACEI versus ARB. There was some 
indication of differential chest X-ray workup in the days around the index date, however, and 
contrary to our expectation, the proportion difference was highest in the month before 
initiation but negligible thereafter. Our study provides some suggestion of potential drug use 
prior to the first recorded pharmacy claim as also observed in some other settings,24 or else 
some tendency for some physicians to assess lung function prior to prescribing ACEI. 
Results may differ in other settings, with different drugs and outcomes. In some scenarios, 
differential diagnostic evaluation may lead to considerable detection bias that uncovers more 
severe outcomes in addition to simply finding a greater number of cases. Analyses like the 
ones presented here will help researchers to evaluate the potential for bias in other data 
sources and drug-outcome relationships where diagnostic suspicion may be suspected.
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• Differential diagnostic evaluation associated with a drug, e.g., based on 
known side effects, may result in biased effect estimates in 
pharmacoepidemiologic studies due to an increased detection of preclinical 
conditions.
• Persistent cough is a common side effect with angiotensin converting 
enzyme inhibitors (ACEI) and we hypothesized that ACEI initiators would 
have more cough-related diagnostic evaluation than initiators of angiotensin 
receptor blockers (ARB), potentially leading to diagnosis of preclinical lung 
cancer.
• Using Medicare beneficiaries 66–99 years of age, who initiated 
monotherapy with ACEI or ARB between 2007 and 2012, this study found 
minimal differences in diagnostic evaluations among initiators of ACEI 
versus ARB in the 6 months after drug initiation and no difference in lung 
cancer incidence over median 0.7 years follow-up, adjusted for a number of 
baseline characteristics.
• Contrary to our expectation, the difference in probabilities of having a chest 
X-ray comparing ACEI versus ARB groups was the highest in the month 
before initiation instead of post-initiation. This may be an indication of 
ACEI exposure prior to the first observed pharmacy claim as seen in some 
other settings, or a tendency of some physicians to assess the lungs prior to 
prescribing ACEI.
• Assessment of diagnostic evaluations before and after the initiation of 
treatments compared will help researchers to evaluate the potential for bias 
in specific pharmacoepidemiologic studies.
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Figure 1. Age, sex, and race adjusted monthly proportion (risk) differences for chest X-rays 
comparing ACEI versus ARB initiators: 2007 – 2012
ACEI – angiotension converting enzyme inhibitors, ARB - angiotensin converting enzyme
CI – Confidence intervals
Index date – Date of the first recorded prescription (initiation date)
Pre – period before initiation
Post – period after initiation
The first month post-index also contains the index date (date of drug initiation)
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